Protalix BioTherapeutics (NYSE:PLX - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued on Tuesday.
Separately, HC Wainwright raised their target price on Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a report on Monday.
Get Our Latest Stock Analysis on PLX
Protalix BioTherapeutics Price Performance
Shares of PLX traded up $0.02 on Tuesday, reaching $2.69. The company's stock had a trading volume of 912,734 shares, compared to its average volume of 723,929. Protalix BioTherapeutics has a 12-month low of $0.82 and a 12-month high of $2.76. The stock has a market capitalization of $198.06 million, a P/E ratio of -20.69 and a beta of 0.75. The stock's 50 day simple moving average is $2.03 and its two-hundred day simple moving average is $1.44.
Institutional Investors Weigh In On Protalix BioTherapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new stake in shares of Protalix BioTherapeutics in the third quarter worth $38,000. Cubist Systematic Strategies LLC purchased a new stake in Protalix BioTherapeutics in the 2nd quarter worth $37,000. Squarepoint Ops LLC raised its holdings in Protalix BioTherapeutics by 673.3% during the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company's stock valued at $161,000 after acquiring an additional 119,949 shares during the period. GSA Capital Partners LLP lifted its position in shares of Protalix BioTherapeutics by 8.5% in the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company's stock valued at $444,000 after acquiring an additional 33,969 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Protalix BioTherapeutics in the second quarter worth about $67,000. Institutional investors own 16.53% of the company's stock.
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Further Reading
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
